Additional Development Work for Product. In the event the NDA filed for the Product results in an “approvable” letter or a succeeding equivalent communication from the FDA in the form of a regulatory decision letter (an “Approvable Letter”), RELIANT shall have the option to either:
Appears in 6 contracts
Samples: Agreement, Agreement (Reliant Pharmaceuticals, Inc.), Agreement (Reliant Pharmaceuticals, Inc.)
